Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06651034
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervains Tenosynovitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervains Tenosynovitis
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
De Quervains tenosynovitis DQT was originally identified by Swiss surgeon Fritz de Quervain in 1895 It is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist In DQT the sheaths surrounding the abductor pollicis longus APL and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist This thickening leads to pain which worsens with thumb movements and radial or ulnar deviation of the wrist Traditional treatment methods such as corticosteroid injections and physical therapy often provide only temporary relief and may not address the underlying inflammation effectively Intralesional platelet rich plasma PRP therapy has emerged as a promising alternative utilizing the patients own growth factors and cytokines to promote healing and reduce inflammation By investigating the efficacy of intralesional PRP in patients with DQT this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times reduce pain and improve functional outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None